Abstract

Computational modeling is an essential component of modern drug discovery. One of its most important applications is to select promising drug candidates for pharmacologically relevant target proteins. Because of continuing advances in structural biology, putative binding sites for small organic molecules are being discovered in numerous proteins linked to various diseases. These valuable data offer new opportunities to build efficient computational models predicting binding molecules for target sites through the application of data mining and machine learning. In particular, deep neural networks are powerful techniques capable of learning from complex data in order to make informed drug binding predictions. In this communication, we describe Pocket2Drug, a deep graph neural network model to predict binding molecules for a given a ligand binding site. This approach first learns the conditional probability distribution of small molecules from a large dataset of pocket structures with supervised training, followed by the sampling of drug candidates from the trained model. Comprehensive benchmarking simulations show that using Pocket2Drug significantly improves the chances of finding molecules binding to target pockets compared to traditional drug selection procedures. Specifically, known binders are generated for as many as 80.5% of targets present in the testing set consisting of dissimilar data from that used to train the deep graph neural network model. Overall, Pocket2Drug is a promising computational approach to inform the discovery of novel biopharmaceuticals.

Highlights

  • Recent developments in genomics revealed novel disease-related molecular targets, many of which are yet to be characterized with respect to the possibility of modulating their functions with pharmaceutical agents

  • This result can be attributed to the fact that capturing longer dependencies in molecular strings is more difficult for the Recurrent neural networks (RNNs) trained to minimize the sum of crossentropy loss function

  • We describe Pocket2Drug, a novel deep learning model employing an encoder-decoder architecture to predict binding molecules for a ligand binding site

Read more

Summary

Introduction

Recent developments in genomics revealed novel disease-related molecular targets, many of which are yet to be characterized with respect to the possibility of modulating their functions with pharmaceutical agents. Another challenge in pharmacotherapy arises from resistance effects to existing drugs complicating the treatment of infectious diseases (Trebosc et al, 2019) and cancer (Shou et al, 2004). Many drug development projects are focused on the discovery of small molecule therapeutics with new mode of action (Gerry and Schreiber, 2018). Generating novel small molecules is a difficult endeavor due to the high complexity of biological systems and the enormous size of chemical space of organic compounds. Even advanced high-throughput screening methods have notable limitations due to the long time and high costs of screening a large number of drug candidates

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call